Clinical Trial Update: A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs [Phase 1]

View source ↗

Summary

Phase 1 dose randomization study evaluating Bulumtatug Fuvedotin in triple-negative breast cancer patients previously treated with antibody-drug conjugates; rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Bulumtatug Fuvedotin

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Triple Negative Breast Cancer | Phase 1 | Status: RECRUITING